JP2007507538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007507538A5 JP2007507538A5 JP2006534206A JP2006534206A JP2007507538A5 JP 2007507538 A5 JP2007507538 A5 JP 2007507538A5 JP 2006534206 A JP2006534206 A JP 2006534206A JP 2006534206 A JP2006534206 A JP 2006534206A JP 2007507538 A5 JP2007507538 A5 JP 2007507538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- conopeptide
- effective amount
- pharmaceutical
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic Effects 0.000 claims description 12
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 7
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 7
- 229960000794 Baclofen Drugs 0.000 claims description 7
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 7
- 229960003150 bupivacaine Drugs 0.000 claims description 7
- 229960002896 clonidine Drugs 0.000 claims description 7
- 238000007913 intrathecal administration Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 229960005181 morphine Drugs 0.000 claims description 6
- 229930014694 morphine Natural products 0.000 claims description 6
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 5
- BPKIMPVREBSLAJ-QTBYCLKRSA-N Ziconotide Chemical group C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 claims description 5
- 229960001410 hydromorphone Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 5
- 229960002811 ziconotide Drugs 0.000 claims description 5
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims description 4
- 229960001736 buprenorphine Drugs 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 20
- 230000003078 antioxidant Effects 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 3
- 229960002428 Fentanyl Drugs 0.000 claims 3
- 229960004739 Sufentanil Drugs 0.000 claims 3
- 206010018691 Granuloma Diseases 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 229960004207 Fentanyl Citrate Drugs 0.000 description 2
- 229960001204 Sufentanil Citrate Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 1
Description
発明の要約
本発明は、ω−コノペプチドと、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、クエン酸フェンタニル、ブプレノルフィンおよびクエン酸スフェンタニルからなる群から選ばれる鎮痛剤、またはその薬学的に許容される塩を含有する医薬製剤であって、該ω−コノペプチドがその効力を維持し、該鎮痛剤と物理的にも、化学的にも共存できる該医薬製剤に関する。該医薬製剤は髄腔内投与に適している。
本発明は、ω−コノペプチドと、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、クエン酸フェンタニル、ブプレノルフィンおよびクエン酸スフェンタニルからなる群から選ばれる鎮痛剤、またはその薬学的に許容される塩を含有する医薬製剤であって、該ω−コノペプチドがその効力を維持し、該鎮痛剤と物理的にも、化学的にも共存できる該医薬製剤に関する。該医薬製剤は髄腔内投与に適している。
本発明は、また疼痛軽減方法を提供する。該方法は、主体にω−コノペプチド、好ましくはジコノチドを、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、クエン酸フェンタニル、ブプレノルフィンおよびクエン酸スフェンタニルからなる群から選ばれる鎮痛剤、またはその薬学的に許容される塩と共に投与するステップを含み、該ω−コノペプチドがその効力を維持し、該鎮痛剤と物理的にも、化学的にも共存できる。好ましい投与経路は、髄腔内投与、特に継続的髄腔内注入である。
他の1つの態様として、疼痛を軽減させる方法は、ω−コノペプチドの有効量と、ブピバカイン、クロニジンおよびバクロフェンからなる群から選択される鎮痛剤またはその薬学的に許容される塩の有効量を、患者に投与するステップを含み、その際の該投与法は継続髄腔内注入である。好ましいω−コノペプチドは、ジコノチドである。ω−コノペプチドとその鎮痛剤は互いに別々の製剤でよく、そして同時に或いは連続して投与されうる。別にω−コノペプチドとその鎮痛剤は、予め混合し、投与用の1つの製剤を形成しうる。
Claims (14)
- ω−コノペプチド、抗酸化剤、および、モルヒネ、ブピバカイン、クロニジン、ハイドロモルホン、バクロフェン、フェンタニル、スフェンタニルおよびブプレノルフィンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩を含有する医薬製剤であって、該ω−コノペプチドがその有効性を維持し、該鎮痛剤と物理的にも、化学的にも共存できる該医薬製剤。
- 該ω−コノペプチドがジコノチドである請求項1に記載の医薬製剤。
- 該医薬製剤が髄腔内投与に適した医薬製剤である請求項1に記載の医薬製剤。
- 該医薬製剤が継続的髄腔内注入に適した医薬製剤である請求項3に記載の医薬製剤。
- 該医薬製剤が薬剤投与用植込み式ポンプ中37℃で少なくとも7日間安定である請求項1に記載の医薬製剤。
- 該鎮痛剤がモルヒネ、クロニジン、ハイドロモルホン、フェンタニルまたはスフェンタニルである請求項1から5のいずれかに記載の医薬製剤。
- 該鎮痛剤がバクロフェンまたはブピバカインである請求項1から5のいずれかに記載の医薬製剤。
- 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、および、ハイドロモルホン、ブプレノルフィン、フェンタニルおよびスフェンタニルからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する医薬製剤。
- 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、および、ブピバカイン、クロニジンおよびバクロフェンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する医薬製剤。
- 患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドの有効量、抗酸化剤、およびモルヒネまたはその薬学的に許容される塩の有効量を含有する医薬製剤。
- 髄腔内アヘン誘導肉芽腫形成に敏感な患者の疼痛を軽減するための医薬製剤であって、該医薬製剤がω−コノペプチドを含有する医薬製剤。
- 該医薬製剤が、更にブピバカイン、クロニジンおよびバクロフェンからなる群から選ばれる鎮痛剤またはその薬学的に許容される塩の有効量を含有する請求項11に記載の医薬製剤。
- 該ω−コノペプチドがジコノチドである請求項8から12のいずれかに記載の医薬製剤。
- 該医薬製剤が、10−25μg/mlのジコノチドおよび7.5−18.75mg/mlのモルヒネを含有する請求項10に記載の医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50862503P | 2003-10-02 | 2003-10-02 | |
US50846903P | 2003-10-03 | 2003-10-03 | |
PCT/US2004/032559 WO2005032556A1 (en) | 2003-10-02 | 2004-10-01 | Method for reducing pain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011129404A Division JP2011173931A (ja) | 2003-10-02 | 2011-06-09 | 疼痛軽減方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007507538A JP2007507538A (ja) | 2007-03-29 |
JP2007507538A5 true JP2007507538A5 (ja) | 2007-11-08 |
Family
ID=34426056
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006534206A Pending JP2007507538A (ja) | 2003-10-02 | 2004-10-01 | 疼痛軽減方法 |
JP2011129404A Pending JP2011173931A (ja) | 2003-10-02 | 2011-06-09 | 疼痛軽減方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011129404A Pending JP2011173931A (ja) | 2003-10-02 | 2011-06-09 | 疼痛軽減方法 |
Country Status (5)
Country | Link |
---|---|
US (14) | US7268109B2 (ja) |
EP (1) | EP1689401A1 (ja) |
JP (2) | JP2007507538A (ja) |
CA (2) | CA2930900C (ja) |
WO (1) | WO2005032556A1 (ja) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
ATE477020T1 (de) | 2002-06-07 | 2010-08-15 | Dyax Corp | Prevention und verringerung von ischemia |
JP2005537006A (ja) | 2002-08-28 | 2005-12-08 | ダイアックス、コープ | 臓器及び組織の保存方法 |
EP1689401A1 (en) | 2003-10-02 | 2006-08-16 | Elan Pharmaceuticals, Inc. | Method for reducing pain |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20060210692A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Baby food composition |
US20060210688A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Dehydrated sports drink powder |
US20060210496A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Compositions for skin protection from ultraviolet damage |
US7666448B2 (en) * | 2005-03-18 | 2010-02-23 | Sakura Properties, Llc | Skin cleansing article |
US20060210697A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Infant formula composition |
US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
US7749545B2 (en) * | 2005-03-18 | 2010-07-06 | Sakura Properties, Llc | Fucoidan compositions and methods for dietary and nutritional supplements |
US7776365B2 (en) * | 2005-03-18 | 2010-08-17 | Sakura Properties, Llc | Article with skin protecting and moisturizing compound |
WO2006110853A2 (en) * | 2005-04-12 | 2006-10-19 | Maren Alianna J | System and method for evidence accumulation and hypothesis generation |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
JP2009523802A (ja) * | 2006-01-17 | 2009-06-25 | リージェンツ オブ ザ ユニバーシティー オブ コロラド | Cns状態のための治療剤の安定製剤の中枢投与 |
US8536445B2 (en) * | 2006-06-02 | 2013-09-17 | Emcore Solar Power, Inc. | Inverted metamorphic multijunction solar cells |
US20080102097A1 (en) * | 2006-10-31 | 2008-05-01 | Zanella John M | Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent |
DK2604257T3 (en) * | 2007-08-07 | 2017-08-28 | Acelrx Pharmaceuticals Inc | ORAL TRANSMUCOSAL DOSAGE FORMS INCLUDING SUFENTANIL AND TRIAZOLAM |
CA2695012A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
CN101412752B (zh) * | 2007-12-26 | 2011-12-07 | 杭州诺泰制药技术有限公司 | 齐考诺肽的固相合成方法 |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US9132119B2 (en) | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US9132085B2 (en) | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8946277B2 (en) * | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US9072727B2 (en) * | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US8629172B2 (en) * | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US20110129508A1 (en) * | 2008-05-06 | 2011-06-02 | Relevare Aust. Pty Ltd | Methods and compositions for the management of pain using omega-conotoxins |
US20110171163A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of ziconotide peptides |
EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
EP2385843A4 (en) | 2009-01-06 | 2013-02-27 | Dyax Corp | TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
PL387984A1 (pl) * | 2009-05-07 | 2010-11-08 | Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan | Nowe kompozycje substancji leczniczych do leczenia bólów przewlekłych |
US8617583B2 (en) * | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8231891B2 (en) * | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
DE102010053416A1 (de) | 2010-12-03 | 2012-06-06 | Friedrich-Schiller-Universität Jena | Verfahren zur Synthese von Cystein-haltigen Peptiden durch Native Chemische Ligation und/oder Oxidation |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
JP2013037571A (ja) | 2011-08-09 | 2013-02-21 | Sony Corp | 情報処理装置、情報処理方法、プログラム、及び情報処理システム |
US9180108B2 (en) | 2011-10-27 | 2015-11-10 | Medtronic, Inc. | Baclofen formulations and methods for making same |
US9155734B2 (en) | 2012-03-07 | 2015-10-13 | Mallinckrodt Llc | Stability of hydromorphone hydrochloride solutions |
WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
US20140296830A1 (en) * | 2013-03-28 | 2014-10-02 | Jazz Pharmaceuticals, Inc. | Methods of administering drugs in an implantable multi-chamber pump |
JP6246640B2 (ja) * | 2014-03-25 | 2017-12-13 | 京セラ株式会社 | 電子機器 |
KR102555955B1 (ko) | 2014-03-27 | 2023-07-18 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
BR102015010089A2 (pt) * | 2015-05-04 | 2017-07-18 | Ministério Da Ciência E Tecnologia | Process for obtaining a product for prevention, paralysis of care injuries and remineralization of teeth and obtained product |
US10519324B2 (en) | 2015-05-22 | 2019-12-31 | Clemson University Research Foundation | Conotoxin peptides for use in biofouling deterrence |
EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US10369157B1 (en) | 2018-03-29 | 2019-08-06 | Mfkc 200, Llc | Multi-agent formulation |
WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US5559095A (en) * | 1989-11-22 | 1996-09-24 | Neurex Corporation | Delayed treatment method of reducing ischemia-related neuronal damage |
US5051403A (en) * | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
US5189020A (en) * | 1989-11-22 | 1993-02-23 | Neurex Corporation | Method of reducing neuronal damage using omega conotoxin peptides |
ATE165977T1 (de) * | 1991-12-30 | 1998-05-15 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
US5824645A (en) * | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
US5471033A (en) * | 1994-04-15 | 1995-11-28 | International Business Machines Corporation | Process and apparatus for contamination-free processing of semiconductor parts |
WO1996024330A1 (en) * | 1995-02-10 | 1996-08-15 | Medtronic, Inc. | Method and device for administering analgesics |
US6054429A (en) * | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
US5795864A (en) * | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
DE69637021T2 (de) | 1995-06-27 | 2008-01-10 | Eisai R&D Management Co., Ltd. | Zusammensetzungen zur Erzielung von Analgesie und zur Hemmung der Progression neuropathischer Schmerzerkrankungen |
US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
WO2001083555A2 (en) * | 2000-05-04 | 2001-11-08 | California Institute Of Technology | Pain signaling molecules |
US20030232871A1 (en) * | 2002-03-15 | 2003-12-18 | Sheikh Ahmad Y. | Crystalline parecoxib sodium |
EP1689401A1 (en) | 2003-10-02 | 2006-08-16 | Elan Pharmaceuticals, Inc. | Method for reducing pain |
US20140296830A1 (en) * | 2013-03-28 | 2014-10-02 | Jazz Pharmaceuticals, Inc. | Methods of administering drugs in an implantable multi-chamber pump |
-
2004
- 2004-10-01 EP EP04794057A patent/EP1689401A1/en not_active Ceased
- 2004-10-01 US US10/956,252 patent/US7268109B2/en active Active
- 2004-10-01 CA CA2930900A patent/CA2930900C/en active Active
- 2004-10-01 CA CA2540895A patent/CA2540895C/en active Active
- 2004-10-01 WO PCT/US2004/032559 patent/WO2005032556A1/en active Search and Examination
- 2004-10-01 JP JP2006534206A patent/JP2007507538A/ja active Pending
-
2007
- 2007-07-31 US US11/831,702 patent/US20070270353A1/en not_active Abandoned
- 2007-07-31 US US11/831,696 patent/US7524812B2/en active Active
-
2009
- 2009-06-12 US US12/483,673 patent/US7833973B2/en active Active
-
2010
- 2010-10-05 US US12/898,525 patent/US7956030B2/en active Active
- 2010-10-05 US US12/898,516 patent/US7977307B2/en active Active
-
2011
- 2011-06-09 JP JP2011129404A patent/JP2011173931A/ja active Pending
- 2011-07-05 US US13/176,568 patent/US8268774B2/en active Active
-
2012
- 2012-09-14 US US13/616,607 patent/US8513198B2/en active Active
-
2013
- 2013-03-08 US US13/791,715 patent/US8653033B2/en active Active
- 2013-12-18 US US14/133,303 patent/US8765680B2/en active Active
-
2014
- 2014-06-20 US US14/310,533 patent/US20140371153A1/en not_active Abandoned
-
2015
- 2015-06-30 US US14/788,524 patent/US9707270B2/en active Active
-
2017
- 2017-07-17 US US15/651,655 patent/US10307463B2/en active Active
-
2019
- 2019-05-02 US US16/402,145 patent/US10857204B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007507538A5 (ja) | ||
JP6212104B2 (ja) | オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤 | |
Pascoe | Opioid analgesics | |
US20180064706A1 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
DK2574167T3 (en) | LIQUID NOSE SPRAY CONTAINING low-dose naltrexone | |
US20070116730A1 (en) | Pharmaceutical compositions | |
JP2005512995A5 (ja) | ||
JP2005515966A5 (ja) | ||
CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
JP2012505883A5 (ja) | ||
WO2011098539A1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
US20180200182A1 (en) | Transmucosal drug delivery devices for use in chronic pain relief | |
CH708257B1 (de) | Zusammensetzung zur Behandlung einer Opioid-induzierten unerwünschten pharmakodynamischen Reaktion. | |
EP3331509A1 (en) | Stable liquid injectable solution of midazolam and pentazocine | |
JP2022516595A (ja) | オピオイドアンタゴニストを送達するための組成物及び方法 | |
JP2007008871A (ja) | 経皮吸収促進組成物 | |
JP2012516288A (ja) | 薬物乱用抑制剤、方法および組成物 | |
US10736874B1 (en) | Methods for treating pain associated with sickle cell disease | |
JP2004043479A (ja) | 経鼻吸収用組成物 | |
CA3130619C (en) | Naloxone formulations for sublingual and/or buccal administration | |
WO2008062453B1 (en) | Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form | |
AU2011254554B2 (en) | Liquid nasal spray containing low-dose naltrexone | |
KR20210003313A (ko) | 만성 통증 완화에 이용되는 점막 관통 약물 전달 장치 | |
JP2009510158A (ja) | 毒物依存症の治療におけるネボグラミンの使用 | |
JP2021536443A (ja) | 高血圧治療をサーカディアンリズムと同期させる |